Suppr超能文献

非小细胞肺癌中的突变发生率和一致性:基于种族和组织学的荟萃分析(mutMap)。

Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap).

机构信息

R&D Genetics, Personalised Healthcare & Biomarkers, AstraZeneca, Macclesfield, UK.

出版信息

Ann Oncol. 2013 Sep;24(9):2371-6. doi: 10.1093/annonc/mdt205. Epub 2013 May 30.

Abstract

BACKGROUND

Meta-analyses were conducted to characterize patterns of mutation incidence in non small-cell lung cancer (NSCLC).

DESIGN

Nine genes with the most complete published mutation coincidence data were evaluated. One meta-analysis generated a 'mutMap' to visually represent mutation coincidence by ethnicity (Western/Asian) and histology (adenocarcinoma [ADC] or squamous cell carcinoma). Another meta-analysis evaluated incidence of individual mutations. Extended analyses explored incidence of EGFR and KRAS mutations by ethnicity, histology, and smoking status.

RESULTS

Genes evaluated were TP53, EGFR, KRAS, LKB1, EML4-ALK, PTEN, BRAF, PIK3CA, and ErbB2. The mutMap highlighted mutation coincidences occurring in ≥5% of patients, including TP53 with KRAS or EGFR mutations in patients with ADC, and TP53 with LKB1 mutation in Western patients. TP53 was the most frequently mutated gene overall. Frequencies of TP53, EGFR, KRAS, LKB1, PTEN, and BRAF mutations were influenced by histology and/or ethnicity. Although EGFR mutations were most frequent in patients with ADC and never/light smokers from Asia, and KRAS mutations were most frequent in patients with ADC and ever/heavy smokers from Western countries, both were detected outside these subgroups.

CONCLUSIONS

Potential molecular pathology segments of NSCLC were identified. Further studies of mutations in NSCLC are warranted to facilitate more specific diagnoses and guide treatment.

摘要

背景

进行荟萃分析以描述非小细胞肺癌(NSCLC)中突变发生率的模式。

设计

评估了具有最完整已发表突变一致性数据的九个基因。一项荟萃分析生成了一个“mutMap”,通过种族(西方/亚洲)和组织学(腺癌[ADC]或鳞状细胞癌)来直观地表示突变一致性。另一项荟萃分析评估了个体突变的发生率。扩展分析探讨了 EGFR 和 KRAS 突变在种族、组织学和吸烟状态下的发生率。

结果

评估的基因包括 TP53、EGFR、KRAS、LKB1、EML4-ALK、PTEN、BRAF、PIK3CA 和 ErbB2。mutMap 突出显示了在≥5%的患者中发生的突变一致性,包括在 ADC 患者中存在 TP53 与 KRAS 或 EGFR 突变,以及在西方患者中存在 TP53 与 LKB1 突变。TP53 是总体上最常突变的基因。TP53、EGFR、KRAS、LKB1、PTEN 和 BRAF 突变的频率受组织学和/或种族的影响。尽管 EGFR 突变在亚洲从不吸烟/轻度吸烟的 ADC 患者中最常见,KRAS 突变在西方从不吸烟/重度吸烟的 ADC 患者中最常见,但这两种突变在这些亚组之外都有检测到。

结论

确定了 NSCLC 的潜在分子病理学亚组。需要进一步研究 NSCLC 中的突变,以促进更具体的诊断并指导治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d27/3755331/a705e58c0465/mdt20501.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验